-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncolytics Reports Enhanced Immune Activity With Pelareorep in Multiple Myeloma Trial

PUBT·11/09/2026 14:30:33
Listen to the news
Oncolytics Reports Enhanced Immune Activity With Pelareorep in Multiple Myeloma Trial
  • Oncolytics Biotech announced Phase 1b/2 trial data showing pelareorep-associated immune activation in heavily pretreated patients with relapsed or refractory multiple myeloma.
  • Analysis showed enhanced antitumor immune activity, alongside tumor-cell changes linked to increased cell death.
  • Patients responding to treatment showed stronger expansion of immune cells, with fewer signs of immune-cell exhaustion than nonresponders.
  • The findings will be presented at the American Society of Hematology annual meeting on December 12, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090930PRIMZONEFULLFEED9872991) on November 09, 2026, and is solely responsible for the information contained therein.